Skip to content ↓

Kurtz elected to Corporation

The MIT Corporation has announced the election of Ronald A. Kurtz, president of Kulite Tungsten Corporation of East Rutherford, NJ, as a term member. The announcement was made after the December 2 meeting of the Corporation.

Mr. Kurtz will complete the term of the late Donald J. Atwood, which runs until June 30, 1998. Mr. Atwood died April 24 at the age of 69.

Mr. Kurtz holds two SB degrees (industrial management, 1955; metallurgy, 1959) and the SM degree (metallurgy, 1960), all from MIT. He has been president of Kulite Tungsten since 1970. The company is a major producer and fabricator of tungsten alloys for use in the aerospace, medical, electronic and sporting goods industries. A Kulite division produces and distributes darts, dart boards and related equipment. Mr. Kurtz is also chairman of Winmau Dartboard Co., Haverhill, England, the major English manufacturer of dart boards, and president of Commerce Graphics Ltd., Inc., of New Jersey, a distributor of fine art photographs.

Mr. Kurtz has been a member of the MIT Council for the Arts since 1983 and was a member of the Educational Council from 1979 to 1987. He is a member of the Corporation Visiting Committee for the Department of Materials Science and Engineering.

A version of this article appeared in the December 7, 1994 issue of MIT Tech Talk (Volume 39, Number 14).

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story